Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 5/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.37 |
| ▸ | FYN | P06241 | 4/20 | 0.37 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406244 | 0.87 | FYN (0.37) | HCRTR1HCRTR2FYNALDH1A1SRC | |
| SCHEMBL2402671 | 0.86 | HRH4 (0.50) | HRH4ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL2405691 | 0.85 | HRH4 (0.44) | HCRTR1HCRTR2HRH4FYNGRK5 | |
| SCHEMBL2404637 | 0.85 | HRH4 (0.48) | HRH4FYNALDH1A1SRC | |
| SCHEMBL2401665 | 0.85 | HRH4 (0.47) | HCRTR1HCRTR2HRH4FYNGRK5 | |
| Hydrochloric Acid SCHEMBL2404771 | 0.84 | HRH4 (0.43) | HCRTR1HCRTR2HRH4FYNGRK5 | |
| SCHEMBL2403888 | 0.79 | HRH4 (0.37) | HCRTR1HCRTR2HRH4FYNSRC | |
| SCHEMBL2401948 | 0.78 | HCRTR1 (0.35) | HCRTR1HCRTR2HRH4FYNGRK5 | |
| SCHEMBL12269517 | 0.76 | PDE10A (0.42) | HRH4 | |
| SCHEMBL2401453 | 0.75 | FYN (0.46) | FYNGRK5ALDH1A1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545058-B1 | TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS | KALYPSYS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HCRTR1 9/4885HCRTR2 12/4885HRH4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.